Drugmakers have paid ever-increasing attention to the environmental impact their manufacturing operations have, looking for ways to lower their carbon footprint and to be improve energy efficiency. Toward that end, France's Sanofi said today that it has a three-year deal to have SUEZ environment improve the environmental and cost performance of its manufacturing sites globally.
Multinational drug firms in Australia faced a string of barbs in hearings held by a Senate panel into transfer pricing that included a reference to a fictitious German World War II prison camp guard.
One of the episodes that got ex-Sanofi CEO Chris Viehbacher fired was his very public run-in with France's unions when he decided jobs cuts were needed in France to trim costs. Now we will see if his successor can fare any better as Olivier Brandicourt tries to cut costs and build revenue for a company that faces challenges.
The top 10 companies producing diabetes meds raked in about $62 billion in global sales in 2014, up 5.1% from the previous year, according to a report from data analytics firm GlobalData. Companies such as Novo Nordisk, Sanofi and Merck lead the pack, posting solid gains for their products as they compete for a piece of a rapidly growing market.
Growth in emerging markets may be slowing, but pharma sales there are still outpacing those everywhere else. And if recent numbers are any indication, AstraZeneca is topping its rivals for emerging markets expansion.
Early on in the cancer drug pricing debates, doctors at Memorial Sloan Kettering Cancer Center made waves by rejecting a new Sanofi colon cancer drug as too expensive for its benefits. Now, the noted hospital has taken its cost-benefit analysis to more than 50 cancer meds.
Japan's National Health Insurance (NHI) has confirmed that a slew of generic versions of Sanofi's Plavix will join the reimbursement list after the latest review, a move tipped by the company in its first-quarter earnings call as well.
Anyone expecting one vaccines maker to pull away from the pack by 2020 had better reconsider. The top four companies--Merck, GlaxoSmithKline, Sanofi and Pfizer--are expected to be within less than one percentage point of each other in total market share, a new report says.
Neil Woodford has pulled out of Sanofi and doubled down on Circassia, snapping up a 13.5% stake in the British allergy specialist. The deals were two of a string of stock sales and buys made by the fund manager as he shuffled his deck in recent weeks.
After last week's expert panel meetings, the FDA may put some label limits on PCSK9 cholesterol drugs. But Sanofi, Regeneron and Amgen can take heart.